Table 2 Baseline characteristics of the patients
|  | Overall (n = 71) |
|---|---|
Dosage | |
 n (15 mg) | 25 (35.2%) |
 n (20 mg) | 46 (64.8%) |
 Diet status (fasted/fed) | 45/26 |
 Male | 35 (49.3%) |
 Age, years | 68 (15) |
 BMI, kg/m2 | 26.26 (4.05) |
Indication | |
 AF | 69 (97.2%) |
 VTE | 4 (5.6%) |
 RFCA | 35 (49.3%) |
 AXA3h | 348.66 (156.21) |
  Case (n = 14) | 508.28 (74.05) |
  Control (n = 14) | 202.11 (76.66) |
  p value | 0.000* |
 Smoking (yes/never/cessation) | 10/54/7 |
Comorbidity | |
 Diabetes | 17 (23.9%) |
 Hyperlipemia | 23 (32.4%) |
 Coronary heart disease | 29 (40.8%) |
Baseline blood tests | |
 HGB, g/L | 133 (24) |
 PLT, 109/L | 188 (65) |
 MPV, fL | 9.1 (1.62) |
Outcomes | |
 Any bleeding | 23 (32.4%) |